CryoCell Selling General Administrative from 2010 to 2024
| CCEL Stock | USD 6.82 0.65 10.53% |
Selling General Administrative | First Reported 1997-02-28 | Previous Quarter 4.3 M | Current Value 4 M | Quarterly Volatility 1.2 M |
Check CryoCell International financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CryoCell International's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Selling General Administrative of 11.2 M or Total Revenue of 18.4 M, as well as many indicators such as Price To Sales Ratio of 1.56, Dividend Yield of 0.2 or Days Sales Outstanding of 80.52. CryoCell financial statements analysis is a perfect complement when working with CryoCell International Valuation or Volatility modules.
CryoCell | Selling General Administrative |
Latest CryoCell International's Selling General Administrative Growth Pattern
Below is the plot of the Selling General Administrative of CryoCell International over the last few years. It is CryoCell International's Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CryoCell International's overall financial position and show how it may be relating to other accounts over time.
| Selling General Administrative | 10 Years Trend |
|
Selling General Administrative |
| Timeline |
CryoCell Selling General Administrative Regression Statistics
| Arithmetic Mean | 13,544,579 | |
| Geometric Mean | 12,258,718 | |
| Coefficient Of Variation | 29.46 | |
| Mean Deviation | 2,542,688 | |
| Median | 14,426,244 | |
| Standard Deviation | 3,990,399 | |
| Sample Variance | 15.9T | |
| Range | 18.2M | |
| R-Value | 0.60 | |
| Mean Square Error | 11.1T | |
| R-Squared | 0.35 | |
| Significance | 0.02 | |
| Slope | 531,500 | |
| Total Sum of Squares | 222.9T |
CryoCell Selling General Administrative History
About CryoCell International Financial Statements
CryoCell International investors utilize fundamental indicators, such as Selling General Administrative, to predict how CryoCell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Selling General Administrative | 19.7 M | 11.2 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in CryoCell Stock
When determining whether CryoCell International is a strong investment it is important to analyze CryoCell International's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CryoCell International's future performance. For an informed investment choice regarding CryoCell Stock, refer to the following important reports:Check out the analysis of CryoCell International Correlation against competitors. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.014 | Earnings Share (1.11) | Revenue Per Share 3.839 | Quarterly Revenue Growth 0.035 | Return On Assets (0) |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.